Pasithea Therapeutics Corp Stock Today
Pasithea Therapeutics is selling for under 0.02 as of the 24th of March 2025; that is 9.89 percent up since the beginning of the trading day. The stock's lowest day price was 0.0182. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of September 2021 | Category Healthcare | Classification Health Care |
Valuation Profit Patterns
Check how we calculate scores
Pasithea Stock Highlights
| CEO Director | Tiago MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Pasithea Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pasithea Therapeutics' financial leverage. It provides some insight into what part of Pasithea Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Pasithea Therapeutics Corp (KTTAW) is traded on NASDAQ Exchange in USA. It is located in 1111 Lincoln Road, Miami Beach, FL, United States, 33139 and employs 8 people. Pasithea Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Pasithea Therapeutics Corp has accumulated about 568.98 K in cash with (13.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Pasithea Therapeutics Probability Of Bankruptcy
Pasithea Therapeutics Historical Income Statement
Pasithea Stock Against Markets
Pasithea Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Pasithea Therapeutics Corporate Management
| Stanley Gloss | Chief Officer | Profile | |
| MD BA | Ex CoFounder | Profile | |
| Tiago Marques | CEO Director | Profile | |
| Daniel Schneiderman | Chief Officer | Profile | |
| Graeme Currie | Chief Officer | Profile |
Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.